Mesenchymal stem cell-derived exosomes (MSC-Exos) are tiny biological particles that show promise as a cell-free therapy for severe and steroid-resistant asthma by regulating the immune system and repairing damaged airway tissue through multiple therapeutic pathways simultaneously.
- Preclinical results: Animal studies showed suppressed inflammation, reduced airway remodeling, decreased hyperresponsiveness, and strengthened airway barriers
- Target population: Designed for patients with severe, non-Th2, or steroid-resistant asthma who fail conventional treatments
- Clinical milestone: World’s first phase 1 trial launched in China in 2025, with 2026 case studies reporting improved lung function and no significant adverse events
A recent scientific review highlights the potential of mesenchymal stem cell-derived exosomes (MSC-Exos) in the treatment of severe and steroid-resistant asthma, potentially transforming care for patients with the disease. According to investigators, MSC-Exos are tiny biological particles capable of regulating the immune system and repairing damaged airway tissue.
Detailed by Chinese researchers in the paper, “The Immunomodulatory Role of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Asthma,” the novel treatment could finally provide the relief many patients are unable to achieve. The paper was published in the International Journal of Nanomedicine.
Although inhaled corticosteroids and biologic drugs have improved outcomes for many patients who have asthmatics, researchers noted that those with severe, non-Th2 or steroid-resistant asthma often continue to experience uncontrolled symptoms and frequent exacerbations.
The review found that MSC-Exos, particularly those derived from human umbilical cord mesenchymal stem cells, may offer an alternative approach by targeting multiple immune pathways simultaneously. Unlike conventional treatments that focus on a single inflammatory molecule, the research team said exosomes carry a diverse cargo of proteins, microRNAs, lipids and other bioactive compounds capable of influencing several disease mechanisms at once.
The paper details how asthma is driven by a complex network of immune imbalances, including disruptions in Th1/Th2 and Th17/Treg immune cell populations, activation of innate lymphoid cells and abnormal macrophage behavior. These processes, the authors noted, contribute to persistent airway inflammation, hyperresponsiveness and long-term structural changes in the lungs. MSC-Exos appear capable of restoring immune balance while reducing inflammation and promoting tissue repair, they said.
Preclinical studies described in the review demonstrated several promising effects. Exosomes were shown to suppress inflammatory pathways, inhibit activation of the NLRP3 inflammasome, reduce airway remodeling and strengthen the airway epithelial barrier. Researchers also observed reductions in airway hyperresponsiveness and mucus production in animal models of asthma.
Of particular interest, they noted, was the role of exosome-delivered microRNAs, including miR-146a-5p and miR-223-3p. These molecules were found to regulate key immune processes, dampen inflammatory signaling and protect airway cells from injury. Additional analysis found MSC-Exos could influence macrophage polarization and promote regulatory T-cell activity, helping to restore immune homeostasis.
The paper also highlighted advances in drug delivery. Among several administration methods evaluated, researchers said nebulized inhalation emerged as the most promising because it delivers exosomes directly to the lungs while minimizing systemic side effects. They believe this approach could improve targeting and treatment efficiency for asthma patients.
This area of science recently reached an important milestone with the launch of what researchers describe as the world’s first phase 1 clinical trial of nebulized MSC-Exos for moderate-to-severe asthma in China in 2025. Early clinical observations have been encouraging, they said. A 2026 case study involving patients with asthma and COPD reported improved lung function with no significant adverse events following nebulized MSC-Exos treatment.
Despite its promise, the study’s authors cautioned that major hurdles remain before exosome therapies become standard medical practice. Most evidence to date comes from laboratory and animal studies. Researchers said questions surrounding manufacturing consistency, quality control, targeted delivery, long-term safety and regulatory approval must still be addressed through large-scale human clinical trials.
